MMP-13 antagonist | BI-4394
ReviewsChemical structure
Highlights
BI-4394 is a highly potent inhibitor of MMP-13 (IC50 = 1 nM) with excellent (>1000 fold) selectivity against several other metalloproteinases and is thus a high quality tool compound for testing biological hypotheses involving this target.
According to the UK Third Generation Cannabinoid Act, the molecule cannot be shipped to the United Kingdom.
Share buttons
Target information
Matrix metalloproteinases (MMPs) are zinc- and calcium-dependent peptidases, involved in the cleavage of collagen, gelatin and other proteins in the extracellular matrix and tissue remodelling. There are approximately 23 known human MMPs that are grouped into subtypes based on their substrates. MMPs have a conserved active site motif where a tris(histidine)-bound zinc(II) acts as the catalytic site for substrate hydrolysis. MMP-13 (also known as collagenase 3, CLG3) is the most efficient enzyme of this class at degrading collagen II, the committed step in articular cartilage degradation and progressive joint damage associated with rheumatoid arthritis (RA). Broad-spectrum MMP inhibitors have failed in clinical trials at least in part due to a joint-stiffening side effect, termed musculoskeletal syndrome (MSS). This was likely due to inhibition of MMPs other than MMP-13 and high selectivity for MMP-13 over other MMPs is therefore favourable.
BI-4394 bound to MMP-13, as observed by X-ray crystallography (PDB code: 5BPA)
In vitro Activity
BI-4394 is a potent inhibitor of MMP-13 with an IC50 value of 1 nM.
|
Probe name / Negative control |
BI-4394 |
BI-4395 |
|
MW [Da] |
446.5 |
374.4 |
|
Inhibition of MMP-13 (IC50) [nM] |
1 |
>26,000 |
|
Inhibition of bovine nasal cartilage with human full length MMP-13 (IC50) [nM] |
31 |
n.d. |
In vitro DMPK parameters
|
Probe name / Negative control |
BI-4394 |
BI-4395 |
||
|
logP (pH 2) |
1.9 |
n.d. |
||
|
Solubility @ pH 7.4 [µg/ml] |
60 |
>96 (pH 7) |
||
|
Solubility @ pH 4 [µg/ml] |
<0.1 |
<0.1 |
||
|
CACO permeability @ pH 7.4 [*10-6 cm/s] |
0.6 |
n.d. |
||
|
CACO efflux ratio |
27 |
n.d. |
||
|
Microsomal stability (human/rat) [% QH] |
40 |
41 |
25 |
n.d. |
|
Plasma protein binding (human) [%] |
98 |
n.d. |
||
In vivo DMPK parameters
|
BI-4394 |
RAT |
|
Clearance [ml/(min*kg)]b |
39 |
|
Mean residence time after iv dose [h] |
0.5 |
|
F [%] |
39 |
|
Vss [l/kg] |
0.4 |
b iv dose: 1 mg/kg
Negative control
BI-4395 which serves as a negative control
Selectivity
BI-4394 is highly (>1000 fold) selective against other matrix metalloproteinases (MMP-1, 2, 3, 7, 8, 9, 10, 12, 14):
|
MMP |
1 |
2 |
3 |
7 |
8 |
9 |
10 |
12 |
13 |
14 |
|
IC50 [µM] |
>22 |
18 |
>22 |
>22 |
>22 |
8.9 |
16 |
>22 |
0.001 |
8.3 |
|
BI-4394 |
Selectivity data available |
|
Cerep® |
Yes |
|
Panlabs® |
No |
|
Invitrogen® |
Yes |
|
DiscoverX® |
No |
|
Dundee |
No |
Invitrogen:
18/56 kinases hit >50 inhibition at 10 µM: STK6 (99%), MAPKAPK2 (99%), RPS6KA3 (95%), MAPK14 (94%), GSK3B (94%), AMPK A1B1G1 (92%), PRKACA (90%), PIM1 (86%), KDR (83%), AKT1 (76%), SRC (75%), DYRK3 (72%), MAP4K4 (68%), MET (57%), JAK3 (56%), IKBKB (52%), ABL1 (52%), NEK1 (51%).
Selectivity data can be downloaded free of charge here.
Co-crystal structure of the BI probe compound and the target protein
X-Ray co-crystal structure of BI-4394 bound to MMP-13 is available (see Figure "BI-4394 bound to MMP-13, as observed by X-ray crystallography (PDB code: 5BPA)", PDB code: 5BPA).
Summary
BI-4394 is a potent and highly selective inhibitor of MMP-13 that can be used as tool compound to test biological hypotheses in vitro.
According to the UK Third Generation Cannabinoid Act, the molecule cannot be shipped to the United Kingdom.
Supplementary data
References
Matrix Metalloproteinases as Modulators of Inflammation and Innate Immunity
William C. Parks, Carole L. Wilson and Yolanda S. López-Boado
Nature Reviews Immunology 2004, 4, 617.
Fragment-Based Discovery of Indole Inhibitors of Matrix Metalloproteinase-13
Steven J. Taylor, Asitha Abeywardane, Shuang Liang, Ingo Muegge, Anil K. Padyana, Zhaoming Xiong, Melissa Hill-Drzewi, Bennett Farmer, Xiang Li, Brandon Collins, John Xiang Li, Alexander Heim-Riether, John Proudfoot, Qiang Zhang, Daniel Goldberg, Ljiljana Zuvela-Jelaska, Hani Zaher, Jun Li, and Neil A. Farrow
J. Med. Chem. 2011, 54, 8174.
Improving potency and selectivity of a new class of non-Zn-chelating MMP-13 inhibitors
Heim-Riether A, Taylor S. J., Liang S., Gao D.A., Xiong Z., Michael August E., Collins B.K., Farmer B.T. 2nd, Haverty K., Hill-Drzewi M., Junker H.D., Mariana Margarit S., Moss N., Neumann T., Proudfoot J.R., Keenan L. S., Sekul R., Zhang Q., Li J., Farrow N. A.
Bioorg. Med. Chem. Lett. 2009, 19, 5321.
SAR studies of non-zinc-chelating MMP-13 inhibitors: Improving selectivity and metabolic stability
Gao D.A., Xiong Z., Heim-Riether A., Amodeo L., August E. M., Cao X., Ciccarelli L., Collins B. K., Harrington K., Haverty K., Hill-Drzewi M., Li X., Liang S., Margarit S.M., Moss N., Nagaraja N., Proudfoot J., Roman R., Schlyer S., Keenan L.S., Taylor S., Wellenzohn B., Wiedenmayer D., Li J., Farrow N. A.
Bioorg. Med. Chem. Lett. 2010, 20, 5039.
Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)- 5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Trea
Ruminski P. G., Massa M., Strohbach J., Hanau C.E., Schmidt M., Scholten J.A., Fletcher T.R., Hamper B.C., Carroll J.N., Shieh H.S., Caspers N., Collins B., Grapperhaus M., Palmquist K. E., Collins J., Baldus J.E., Hitchcock J., Kleine H.P., Rogers M.D., McDonald J., Munie G.E., Messing D. M., Portolan S., Whiteley L. O., Sunyer T. and Schnute M. E.
J. Med. Chem. 2016, 59, 313.
